Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study ; volume:41 ; number:2 ; day:9 ; month:3 ; year:2023 ; pages:306-316 ; date:4.2023
Investigational new drugs ; 41, Heft 2 (9.3.2023), 306-316, 4.2023
- Creator
-
Yang, James Chih-Hsin
Su, Wu-Chou
Chiu, Chao-Hua
Shiah, Her-Shyong
Lee, Kang-Yun
Hsia, Te-Chun
Uno, Makiko
Crawford, Nigel
Terakawa, Hiroshi
Chen, Wen-Chi
Takayama, Gensuke
Hsu, Ching
Hong, Ying
Saintilien, Carline
McGill, Joseph
Chang, Gee-Chen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-023-01341-y
- URN
-
urn:nbn:de:101:1-2023090321220697323805
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yang, James Chih-Hsin
- Su, Wu-Chou
- Chiu, Chao-Hua
- Shiah, Her-Shyong
- Lee, Kang-Yun
- Hsia, Te-Chun
- Uno, Makiko
- Crawford, Nigel
- Terakawa, Hiroshi
- Chen, Wen-Chi
- Takayama, Gensuke
- Hsu, Ching
- Hong, Ying
- Saintilien, Carline
- McGill, Joseph
- Chang, Gee-Chen
- SpringerLink (Online service)
Other Objects (12)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Axl Rose
Axl Leskoschek
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Axl Rose
Axl Leskoschek
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Axl Rose
Axl Leskoschek
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC